Neurology Today in 5

Artificial sweeteners cognition concerns, drug company payments and prescribing decisions, graphene technology

Neurology Today in 5

Show Notes

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about artificial sweeteners' impact on cognitive health, how drug company payments influence prescribing decisions, and the use of graphene technology to accelerate maturation of neurons.

More from Neurology Today in 5

Oct 15, 2026

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the use of lamotrigine during pregnancy, the value of professional mentorship, and the misdiagnosis of CADASIL as multiple sclerosis.

Oct 1, 2026

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the pros and cons of wearable devices, new data for thrombectomy use in medium-vessel occlusion strokes, and a new treatment for limb-girdle muscular dystrophy type 2I/R9.

Sep 17, 2026

In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the first oral PCSK9 inhibitor, the transforming role of the neurology department chair, and anti-IgLON5 disease.

Sep 3, 2026

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about new migraine prevention guidelines, the use of plasmapheresis for acute MOGAD attacks, and how sabbaticals can help neurologists avoid burnout.

Aug 20, 2026

In this episode, editor-in-chief Joseph E. Safdieh, MD, FAAN, highlights articles about the impact of the "One Big Beautiful Bill Act" on neurology practice and research, how artificial intelligence is transforming the neurologist's workload, and the relationship between GBA1 mutations and Parkinson's disease.

See all episodes →